Spots Global Cancer Trial Database for Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Official Title: Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC
Study ID: NCT00601159
Conditions
Interventions
Study Description
Brief Summary: Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as first line therapy in patients with triple-negative MBC. 80 patients will be treated into this study.
Detailed Description: Triple-negative breast tumors could contribute to the poor prognosis comparing with luminal A breast cancer.Fewer study has revealed that Cisplatin-based therapy may be effective for this type breast cancer.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Contact Details
Name: Zhonghua Wang, MD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
